Analyst Ratings for Rhythm Pharmaceuticals (RYTM)
RYTM Rating Summary
RYTM Price Target Summary
- Highest: $157.00 (Goldman Sachs)
- Lowest: $105.00 (H.C. Wainwright)
- Average: $138.60
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$138.60 (+30.6%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 90%
Avg. $ Target:
$138.60 (+30.6%)
* Over Last 12-Mos
Rating Score: 9.4 / 10
Percentile Rank: 90%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/27/2026 | JPMorgan | Priyanka Grover | New Coverage | Overweight (N/A) |
145.00 (N/A) |
102.66 (106.13) |
3.38% | Details |
| 2/18/2026 | RBC Capital » Updated 7/7/2026 |
Lisa Walter | New Coverage | Outperform (N/A) |
141.00 (137.00) |
102.53 (106.13) |
3.51% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
